文献速递骨质疏松与代谢性骨病

低密度脂蛋白受体相关蛋白5(LRP5)功能获得性突变对葡萄糖和脂质稳态的影响

Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis.
PubMed 文献 · Osteoporos Int · 2017-03-10

结果显示胰岛素敏感性指标无显著差异,但患者血清低密度脂蛋白(LDL)显著降低(p=0.04)。在人类胰岛中,Wnt处理未改变葡萄糖刺激的胰岛素分泌。

要点

  • LRP5功能获得性突变未改善胰岛素敏感性,HOMA-IR、HOMA-B、ISI等指标与对照无显著差异。
  • 患者血清LDL显著低于对照(p=0.04),总胆固醇、甘油三酯、HDL无显著差异。
  • 人类胰岛中Wnt处理未影响第一相或第二相胰岛素分泌AUC。

核心结论

  • 数据不支持LRP5功能获得性突变改善人类葡萄糖代谢的假说。
  • LRP5变异可能影响LDL代谢,但分子机制需进一步研究。

研究设计与样本

  • 匹配病例对照研究,纳入11例LRP5功能获得性突变致高骨量个体(9男2女,平均年龄55±7岁,平均BMI 27.2±2.0)。
  • 排除2例接受胰岛素治疗的2型糖尿病患者。
  • 在学术医学中心进行检测,并评估Wnt处理对原代人类胰岛胰岛素分泌的影响。

主要发现

  • 糖化血红蛋白(HbA1c)p=0.06、估算平均血糖(eAG)p=0.06、胰岛素p=0.82、HOMA-B p=0.34、HOMA-IR p=0.66,均无统计学显著差异。
  • 胰岛素敏感性指数(ISI)均值在两组间相似。
  • 总胆固醇p=0.43、甘油三酯p=0.56、HDL p=0.32,均无显著差异。
  • 血清LDL均值在患者组显著降低(p=0.04)。
  • 小样本亚组通过质子磁共振波谱(MRS)定量显示肌内和肝脏脂质含量在两组间相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者自述样本量小。
  • 作者指出阐明该效应的分子机制需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: LRP5 loss-of-function mutations have been shown to cause profound osteoporosis and have been associated with impaired insulin sensitivity and dysregulated lipid metabolism. We hypothesized that gain-of-function mutations in LRP5 would also affect these parameters. We therefore studied individuals with LRP5 gain-of-function mutations exhibiting high bone mass (HBM) phenotypes and found that while there was no detected change in insulin sensitivity, there was a significant reduction in serum LDL. INTRODUCTION: Wnt signaling through LRP5 represents a newly appreciated metabolic pathway, which potentially represents a target for drug discovery in type 2 diabetes and hyperlipidemia. Studies in animal models suggest a physiologic link between LRP5 and glucose and lipid homeostasis; however, whether it plays a similar role in humans is unclear. As current literature links loss-of-function LRP5 to impaired glucose and lipid metabolism, we hypothesized that individuals with an HBM-causing mutation in LRP5 would exhibit improved glucose and lipid homeostasis. Since studies in animal models have suggested that Wnt signaling augments insulin secretion, we also examined the effect of Wnt signaling on glucose-stimulated insulin secretion on human pancreatic islets. METHODS: This was a matched case-control study. We used several methods to assess glucose and lipid metabolism in 11 individuals with HBM-causing mutations in LRP5. Affected study participants were recruited from previously identified kindreds with HBM-causing LRP5 mutations and included 9 males and 2 females. Two subjects that were being treated with insulin for type 2 diabetes were excluded from our analysis, as this would have obscured our ability to determine the impact of gain-of-function LRP5 mutations on glucose metabolism. The mean age of the evaluated study subjects was 55 ± 7 with a mean BMI of 27.2 ± 2.0. Control subjects were matched and recruited from the general community at an equivalent ratio, with 18 males and 4 females (mean age 56 ± 4; mean BMI 27.2 ± 1.0). Study testing was conducted at an academic medical center. RESULTS: There were no statistically significant differences between affected and matched control populations for HbA1c (p = 0.06), eAG (p = 0.06), insulin (p = 0.82), HOMA-B (p = 0.34), or HOMA-IR (p = 0.66). The mean Insulin Sensitivity Index (ISI) was also similar between control and affected individuals. Total cholesterol (p = 0.43), triglycerides (TG) (p = 0.56), and HDL (p = 0.32) were not different between the same two groups. In a small subset of studied subjects, intramyocellular and hepatic lipid content were similar in the affected individuals and controls when quantified by proton magnetic resonance spectroscopy (MRS). However, the mean value for serum LDL was significantly lower (p = 0.04) in affected individuals. In primary human islets, there were no differences between control and Wnt treatment groups for insulin secretion measured as area under the curve (AUC) for first phase (p = 0.17) or second phase (p = 0.33) insulin secretion. CONCLUSIONS: Although our sample size was small, our data do not support the hypothesis that HBM-causing LRP5 mutations, associated with increased Wnt signaling, improve glucose metabolism in humans. However, it does appear that LRP5 variants may affect LDL metabolism, a major risk factor for coronary artery disease. The molecular mechanisms underpinning this effect warrant further study.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Foer D, Zhu M, Cardone RL, et al. Impact of gain-of-function mutations in the low-density lipoprotein receptor-related protein 5 (LRP5) on glucose and lipid homeostasis. Osteoporos Int. 2017. PMID: 28283687. doi:10.1007/s00198-017-3977-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。